Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/72452
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion |
Author: | Fitter, S. Vandyke, K. Gronthos, S. Zannettino, A. |
Citation: | Journal of Molecular Endocrinology, 2012; 48(3):229-240 |
Publisher: | Soc Endocrinology |
Issue Date: | 2012 |
ISSN: | 0952-5041 1479-6813 |
Statement of Responsibility: | Stephen Fitter, Kate Vandyke, Stan Gronthos and Andrew C W Zannettino |
Abstract: | Improved glucose and lipid metabolism is a unique side effect of imatinib therapy in some chronic myeloid leukaemia (CML) patients. We recently reported that plasma levels of adiponectin, an important regulator of insulin sensitivity, are elevated following imatinib therapy in CML patients, which could account for these improved metabolic outcomes. Adiponectin is secreted exclusively from adipocytes, suggesting that imatinib modulates adiponectin levels directly, by transcriptional upregulation of adiponectin in pre-existing adipocytes, and/or indirectly, by stimulating adipogenesis. In this report, we have demonstrated that imatinib promotes adipogenic differentiation of human mesenchymal stromal cells (MSCs), which in turn secrete high-molecular-weight adiponectin. Conversely, imatinib does not stimulate adiponectin secretion from mature adipocytes. We hypothesise that inhibition of PDGFRα (PDGFRA) and PDGFRβ (PDGFRB) is the mechanism by which imatinib promotes adipogenesis. Supporting this, functional blocking antibodies to PDGFR promote adipogenesis and adiponectin secretion in MSC cultures. We have shown that imatinib is a potent inhibitor of PDGF-induced PI3 kinase activation and, using a PI3 kinase p110α-specific inhibitor (PIK-75), we have demonstrated that suppression of this pathway recapitulates the effects of imatinib on MSC differentiation. Furthermore, using mitogens that activate the PI3 kinase pathway, or MSCs expressing constitutively activated Akt, we have shown that activation of the PI3 kinase pathway negates the pro-adipogenic effects of imatinib. Taken together, our results suggest that imatinib increases plasma adiponectin levels by promoting adipogenesis through the suppression of PI3 kinase signalling downstream of PDGFR. |
Keywords: | Adipocytes Mesenchymal Stem Cells Humans Benzamides Sulfonamides Hydrazones Piperazines Pyrimidines Receptors, Platelet-Derived Growth Factor Platelet-Derived Growth Factor Mitogens Protein Kinase Inhibitors Cell Differentiation Enzyme Activation Molecular Weight Adipogenesis Proto-Oncogene Proteins c-akt Adiponectin Imatinib Mesylate Phosphoinositide-3 Kinase Inhibitors |
Rights: | © 2012 Society for Endocrinology |
DOI: | 10.1530/JME-12-0003 |
Published version: | http://dx.doi.org/10.1530/jme-12-0003 |
Appears in Collections: | Aurora harvest 5 Medical Sciences publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.